Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance
The Pharma Data
AUGUST 3, 2021
The company announced donanemab received Breakthrough Therapy designation for treatment of Alzheimer’s disease and its intention to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. Loxo Oncology at Lilly and Kumquat Biosciences Inc.
Let's personalize your content